医学
酒精性肝病
肝硬化
胃肠病学
内科学
肝病
酒精性肝炎
危险系数
比例危险模型
生存分析
禁欲
酒
置信区间
精神科
化学
生物化学
作者
Ares Villagrasa,Virginia Hernández‐Gea,Ramón Bataller,Álvaro Giráldez Gallego,Bogdan Procopeţ,Lucio Amitrano,Càndid Villanueva,Dominique Thabut,Luis Ibáñez,Agustı́n Albillos,Christophe Bureau,Jonel Trebicka,Elba Llop,Wim Laleman,José M. Palazón,José Castellote,Susana Rodrigues,Lise Lotte Gluud,Carlos Noronha Ferreira,Núria Cañete
摘要
Abstract Background & Aims Alcohol‐related hepatitis (AH) encompasses a high mortality. AH might be a concomitant event in patients with acute variceal bleeding (AVB). The current study aimed to assess the prevalence of AH in patients with AVB and to compare the clinical outcomes of AH patients to other alcohol‐related liver disease (ALD) phenotypes and viral cirrhosis. Methods Multicentre, observational study including 916 patients with AVB falling under the next categories: AH ( n = 99), ALD cirrhosis actively drinking (d‐ALD) ( n = 285), ALD cirrhosis abstinent from alcohol (a‐ALD) ( n = 227) and viral cirrhosis ( n = 305). We used a Cox proportional hazards model to calculate adjusted hazard ratio (HR) of death adjusted by MELD. Results The prevalence of AH was 16% considering only ALD patients. AH patients exhibited more complications. Forty‐two days transplant‐free survival was worse among AH, but statistical differences were only observed between AH and d‐ALD groups (84 vs. 93%; p = 0.005), when adjusted by MELD no differences were observed between AH and the other groups. At one‐year, survival of AH patients (72.7%) was similar to the other groups; when adjusted by MELD mortality HR was better in AH compared to a‐ALD (0.48; 0.29–0.8, p = 0.004). Finally, active drinkers who remained abstinent presented better survival, independently of having AH. Conclusions Contrary to expected, AH patients with AVB present no worse one‐year survival than other patients with different alcohol‐related phenotypes or viral cirrhosis. Abstinence influences long‐term survival and could explain these counterintuitive results.
科研通智能强力驱动
Strongly Powered by AbleSci AI